MX2020003741A - Sales novedosas. - Google Patents

Sales novedosas.

Info

Publication number
MX2020003741A
MX2020003741A MX2020003741A MX2020003741A MX2020003741A MX 2020003741 A MX2020003741 A MX 2020003741A MX 2020003741 A MX2020003741 A MX 2020003741A MX 2020003741 A MX2020003741 A MX 2020003741A MX 2020003741 A MX2020003741 A MX 2020003741A
Authority
MX
Mexico
Prior art keywords
salts
novel salts
methyl
novel
diazaspiro
Prior art date
Application number
MX2020003741A
Other languages
English (en)
Spanish (es)
Inventor
Michael Williams
Kalyan Vasudevan
Gerard M P Giblin
David T Macpherson
David R Witty
Julian Northen
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of MX2020003741A publication Critical patent/MX2020003741A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2020003741A 2017-09-28 2018-09-28 Sales novedosas. MX2020003741A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762564744P 2017-09-28 2017-09-28
PCT/US2018/053520 WO2019067961A1 (en) 2017-09-28 2018-09-28 NEW SALTS

Publications (1)

Publication Number Publication Date
MX2020003741A true MX2020003741A (es) 2021-01-08

Family

ID=65902742

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003741A MX2020003741A (es) 2017-09-28 2018-09-28 Sales novedosas.

Country Status (14)

Country Link
US (1) US20200255438A1 (enExample)
EP (1) EP3687533A4 (enExample)
JP (1) JP2020536070A (enExample)
KR (1) KR20200060404A (enExample)
CN (1) CN111343978A (enExample)
AU (2) AU2018338884A1 (enExample)
BR (1) BR112020005992A2 (enExample)
CA (1) CA3074923A1 (enExample)
EA (1) EA202090853A1 (enExample)
IL (1) IL273520A (enExample)
MA (1) MA50669A (enExample)
MX (1) MX2020003741A (enExample)
SG (1) SG11202002200UA (enExample)
WO (1) WO2019067961A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3077088A1 (en) 2017-10-10 2019-04-18 Biogen Inc. Process for preparing spiro derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2789711C (en) * 2010-02-17 2014-08-05 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
EA201491990A1 (ru) * 2012-05-03 2015-02-27 Новартис Аг L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов
GB201209015D0 (en) * 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds

Also Published As

Publication number Publication date
AU2023202293A1 (en) 2023-05-11
EP3687533A4 (en) 2021-01-20
JP2020536070A (ja) 2020-12-10
MA50669A (fr) 2020-08-05
AU2018338884A1 (en) 2020-04-16
IL273520A (en) 2020-05-31
KR20200060404A (ko) 2020-05-29
SG11202002200UA (en) 2020-04-29
CA3074923A1 (en) 2019-04-04
BR112020005992A2 (pt) 2020-09-29
US20200255438A1 (en) 2020-08-13
EA202090853A1 (ru) 2020-08-27
CN111343978A (zh) 2020-06-26
WO2019067961A1 (en) 2019-04-04
EP3687533A1 (en) 2020-08-05

Similar Documents

Publication Publication Date Title
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
UY36371A (es) Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
CL2018000292A1 (es) Compuestos farmacéuticos
CY1120611T1 (el) Κρυσταλλικες μορφες 1-(5'-(5-(3,5-διχλωρο-4-φθοροφαινυλο)-5-(τριφθορομεθυλο)-4,5-διυδροϊσοξαζολ-3-υλο)-3ή-σπειρο[αζετιδιν-3,1'-ισοβενζοφουραν]-1-υλο)-2-(μεθυλοσουλφονυλ)αιθανονης
CL2017003402A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
HN2006018410A (es) Nuevos derivados del fluoreno, composiciones que los contienen y utilizacion
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
AR094997A1 (es) Sales y formas sólidas de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y composiciones que las comprenden y sus usos
MX2018015252A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
EA202091324A1 (ru) Комбинация 4-пиримидинсульфамидного производного с ингибитором sglt-2 для лечения заболеваний, связанных с эндотелином
ECSP099357A (es) COMPUESTOS QUE MODULAN ACTIVIDAD C-FMS y/o C-KIT Y USOS PARA ELLO
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2015000942A1 (es) Compuestos de benceno sustituido.
BR112014030655A8 (pt) Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
PE20151429A1 (es) Dihidropirimidinonas biciclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofilica
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
CR8986A (es) Isoxazoles sustituidos como fungicidas
BR112015003655A2 (pt) composto; uso de um composto; e composição farmacêutica
MA40281B1 (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
ECSP17010481A (es) Novedosas pirimidinas 2,5-sustituidas